Abstract
Advanced cancers of the prostate and breast commonly progress by metastasizing to the skeleton, where they are incurable but cause serious morbidity and contribute to mortality. Growth of tumor in bone takes several years, opening a large window for pharmaceutical prevention of metastatic progression. Bone provides a unique microenvironment for tumor growth, including niches occupied by hematopoietic and mesenchymal stem cells. Recent data suggest that circulating tumor cells usurp these niches and compete with the normal stem cell occupants. Agents that encourage normal hematopoiesis or bone formation could inhibit colonization of bone by tumor stem cells and prevent or delay metastatic progression. It may be possible to develop high-throughput assays to test compounds for their ability to suppress tumor stem cell occupation of skeletal niches, thus decreasing metastatic progression in at-risk patients.
Keywords: Bone metastases, Stem cell niche, Hematopoietic niche, Endosteal niche, Mesenchymal cell niche, Prostate cancer, Breast cancer, Anti-resorptive agents, Bone-anabolic agents, SKELETON
Anti-Cancer Agents in Medicinal Chemistry
Title: The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Volume: 12 Issue: 3
Author(s): John M. Chirgwin
Affiliation:
Keywords: Bone metastases, Stem cell niche, Hematopoietic niche, Endosteal niche, Mesenchymal cell niche, Prostate cancer, Breast cancer, Anti-resorptive agents, Bone-anabolic agents, SKELETON
Abstract: Advanced cancers of the prostate and breast commonly progress by metastasizing to the skeleton, where they are incurable but cause serious morbidity and contribute to mortality. Growth of tumor in bone takes several years, opening a large window for pharmaceutical prevention of metastatic progression. Bone provides a unique microenvironment for tumor growth, including niches occupied by hematopoietic and mesenchymal stem cells. Recent data suggest that circulating tumor cells usurp these niches and compete with the normal stem cell occupants. Agents that encourage normal hematopoiesis or bone formation could inhibit colonization of bone by tumor stem cells and prevent or delay metastatic progression. It may be possible to develop high-throughput assays to test compounds for their ability to suppress tumor stem cell occupation of skeletal niches, thus decreasing metastatic progression in at-risk patients.
Export Options
About this article
Cite this article as:
M. Chirgwin John, The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228797
DOI https://dx.doi.org/10.2174/187152012800228797 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry DNAM-1 (CD226): A Two-Sword Fencer for Innate and Adaptive Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Extracellular Citrate in Health and Disease
Current Molecular Medicine Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets The Architectural Organization of Human Stem Cell Cycle Regulatory Machinery
Current Pharmaceutical Design Exploring the Anti-Neuroinflammatory Potential of Steroid and Terpenoid-Derived Phytochemicals to Combat Alzheimer's Disease
Current Pharmaceutical Design Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Imaging Methods in Gene Therapy of Cancer
Current Gene Therapy DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance
Current Enzyme Inhibition From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Nanotechnology for Alzheimer Disease
Current Alzheimer Research The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Current Drug Targets Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Molecular Properties and Medical Applications of Peptide Nucleic Acids
Mini-Reviews in Medicinal Chemistry